Is It Too Late to Buy Hims & Hers Health Stock?
Triple-digit investment returns have become rare in this bear market, but that's precisely what telehealth company Hims & Hers Health (NYSE: HIMS) has delivered; the stock is up almost 250% from its 52-week low. Wall Street sold the stock into the ground but couldn't deny the company's excellent operating results in recent quarters.
Naturally, one might assume that chasing a stock up so much in such little time is dangerous, and it can be. However, the evidence shows that Hims & Hers might be an exception worth making. Here is why the stock's hot run might not be over yet.
After the pandemic caused abnormal growth spurts for companies throughout Wall Street, 2022 was a year of reckoning. Many companies saw growth dramatically slow against tough year-over-year comparables and tailwinds that faded as the world returned to normal. In that light, it's understandable that some might doubt Hims & Hers.
Source Fool.com
